SOURCE: SinoFresh Healthcare, Inc.

December 10, 2007 13:56 ET

SinoFresh Interviewed by The Tampa Tribune Concerning MRSA "Super Bug" Cure

ENGLEWOOD, FL--(Marketwire - December 10, 2007) - Charles Fust, Chief Executive Office of SinoFresh HealthCare, Inc. (OTCBB: SFSH), will be featured in an exclusive interview with the Tampa Tribune scheduled for Dec. 14th for a special edition regarding MRSA "Super Bug."

This is the first time SinoFresh Healthcare will be linked with the disease. To read more about MRSA pick up a copy or visit the paper online at

About SinoFresh HealthCare, Inc.

SinoFresh HealthCare, Inc. (OTCBB: SFSH) is a developer and marketer of innovative upper respiratory system therapies. The company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms that are suspected to cause pathogenesis of the mouth, nose and throat. The company's lead product, SinoFresh™ Nasal and Sinus Care, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh™ products are available in Rite Aid, CVS, Duane Reade and other drug, grocery and mass merchandise retailers. More information is available at

Forward-looking statements

Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including risks summarized in the Company's Annual Report on Form 10-KSB for its fiscal year ended December 31, 2006, (file No. 0-49764). The Company's actual results could differ materially from such forward-looking statements. The company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments. Adjusted EBITDA is not a measure of performance calculated in accordance with accounting principles generally accepted in the United States, or "GAAP."

Contact Information